Argentum Medical has presented second reexamination results of its US 7,230,153 C1 patent for Silverlon antimicrobial wound, burn and surgical dressings.
The company confirmed that not only were their original claims confirmed as amended, but newly filed claims were also found patentable.
Argentum Medical CEO Gregg Silver said the US Patent and Trade Office (USPTO) has once again, closely examined their technology and found it worthy of protection.
"We expect to enforce our intellectual property as well as market new products in the year ahead," Silver said.
"This development allow us to move forward with all products and ensure the marketplace receives only genuine Silverlon products."